Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
You may also be interested in...
A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.
The Maryland CNS company got an FDA approval for its second epilepsy product and will begin marketing the drug before the close of the third quarter.
Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.